Corcept Therapeutics Incorporated research snapshot
CORT AI stock analysis reads Corcept Therapeutics as a commercial-stage cortisol-modulation company transitioning from a one-product Cushing’s business into a two-product endocrine and oncology platform, which is what this Corcept Therapeutics AI stock analysis attempts to value. At the August 3, 2026 data cutoff, the latest verified market close was $114.49 on July 31, the calculated market capitalization was about $12.38 billion, and the stock had just rallied roughly 27 percent on July 30 after Q2 2026 earnings beat expectations, raised full-year guidance, and showed a strong first full quarter of Lifyorli sales. The fundamental story improved, but the price now reflects a successful oncology launch, a December PDUFA for relacorilant in Cushing’s syndrome, and continued pipeline progress. This page is informational research, not investment advice.
Current price
$114.49 close on July 31, 2026
Market cap
$12.38 billion
AI score
72 / 100
Rating
Two approved products with a fast Lifyorli launch, but the stock already prices in a lot of execution
Trend status
Strong uptrend, extended after the post-earnings spike
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Corcept sells cortisol-modulating medicines and funds a growing research platform from Korlym revenue. Lifyorli adds a second approved product and a real oncology revenue stream that reached $47.6 million in its first full quarter, but the commercial base is still concentrated in two molecules. | Medium-high |
| Moat | The moat is specialized cortisol biology, clinical know-how, patents, NCCN guideline inclusion, physician education, and rare-disease commercial infrastructure. It is narrower than a network-effect moat and can weaken through generic competition, pricing pressure, or failed trials. | Medium |
| Management | CEO and President Joseph K. Belanoff and CFO Atabak Mokari are steering a net-cash company through a fast oncology launch, a December Cushing’s PDUFA, and a broad pipeline. Insiders owned about 10.77 percent of the company in the latest statistics snapshot, aligning incentives but concentrating influence. | Medium-high |
| Financial trend | FY2025 revenue rose to $761.4 million while net income fell to $99.7 million. Q2 2026 revenue reached $256.1 million, up 32 percent, with net income of $43.0 million, and management raised 2026 guidance to $1.1 to $1.2 billion. | High |
| Valuation | At $114.49, CORT traded near 252x trailing EPS, 14.9x trailing sales, and 115.8x trailing free cash flow, with a forward P/E near 29x. The market is pricing an earnings inflection from Lifyorli and the pipeline, not just current Korlym cash flow. | High |
| Technical trend | Price was above the reported 50-day moving average of $83.74 and 200-day moving average of $61.81, with RSI near 71.3 and the 52-week high at $122.21 set on July 30. Momentum is strong, but the setup is extended after the earnings spike. | Medium-high |
| Risk level | Risk is high because launch execution, the December Cushing’s PDUFA, trial readouts, Korlym generic and rebate pressure, legal matters, short interest near 8.7 percent of shares, and valuation can all move the stock materially. | High |
| AI confidence | AI confidence is high for descriptive filings and published regulatory and analyst events, and medium for scenario outcomes that depend on clinical, commercial, and market variables. | High data confidence |
| Investment certainty | Investment certainty is below the data confidence because CORT needs Lifyorli to keep ramping and the Cushing’s and pipeline programs to deliver to justify the elevated multiple. | Medium |
CORT AI stock forecast
The CORT AI stock forecast is a scenario framework, not a price promise. The market-implied forward earnings estimate was about $3.95 per share at the forward P/E of about 29x, and an audited three-year model using that base returned an illustrative bullish value near $437, a base value near $205, and a bearish value near $82. The ranges below are narrower and anchored to current analyst targets because launch adoption, the December PDUFA, clinical data, and biotech multiples can change quickly.
$140 to $180
More likely if Lifyorli demand keeps accelerating, the Cushing’s NDA is approved at the December 17, 2026 PDUFA date, MONARCH MASH and BELLA data stay positive, revenue beats the raised guidance, and earnings compound toward the $161 to $165 targets from Canaccord, Piper Sandler, and H.C. Wainwright.
$100 to $135
More likely if Lifyorli ramps steadily but normalizes, Cushing’s review completes on the extended timeline, operating expenses stay elevated, and the market holds the near-$135 consensus price target while earnings inflect gradually.
$50 to $85
More likely if Lifyorli uptake disappoints after the launch spike, relacorilant receives another regulatory setback, Korlym pricing and volume fall under generics and government rebates, pipeline trials fail, or investors compress the multiple toward the Wolfe Research $50 target.
CORT AI technical analysis
CORT AI technical analysis is constructive but extended as of the August 3, 2026 cutoff. The July 31 close of $114.49 was above the reported 50-day average of $83.74 and 200-day average of $61.81. RSI was 71.30, average 20-day volume was about 1.39 million shares, and the 52-week range was $28.66 to $122.21. The stock gapped up about 27 percent on July 30 after Q2 results and pulled back on July 31. Confirm levels on a live chart because this page uses static data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $114.49 | NASDAQ close on July 31, 2026, used for the market cap and valuation calculations at the August 3 cutoff. |
| Near resistance | $118.32 to $122.21 | The July 30 close and the $122.21 intraday 52-week high are the first overhead area after the post-earnings spike. |
| Round-number resistance | $125.00 | This psychological level can become supply if price clears the July 30 high. |
| Near support | $104.75 | The July 30 low is the first visible pullback reference inside the earnings gap zone. |
| Consolidation support | $91.00 to $96.00 | Late-July closing levels formed the pre-earnings range that now acts as a deeper support area. |
| 50-day moving average | $83.74 | A close below this reported moving average would weaken the near-term trend and increase mean-reversion risk. |
| 200-day moving average | $61.81 | This is the longer-term trend filter from the August 2026 technical snapshot. |
| Momentum | RSI 71.30, positive but overbought | Price strength is supported by the move above both moving averages, while the high RSI raises pullback risk after the spike. |
| Volume | About 1.39 million shares average over 20 days | Volume spiked to about 4.48 million on July 30. Breakouts and reversals are more credible when volume stays elevated. |
| Volatility | Beta 0.46, with biotech event risk | Beta has been below the market average, but the December PDUFA, trial readouts, and launch metrics can produce gaps that beta does not capture. |
| Invalidation | Close below $83.74, then $61.81 | A break below the 50-day average weakens the short-term setup. A sustained break below the 200-day average challenges the longer-term trend. |
CORT AI trading strategy
The CORT AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with Lifyorli launch metrics, regulatory milestones, cash use, and position sizing because a single clinical, FDA, or launch headline can overwhelm ordinary chart signals.
Watch for price to hold above the $104.75 support and clear the $118.32 to $122.21 resistance zone with expanding volume. A failed breakout is less informative than a close back below the breakout area.
Use a predefined invalidation level and reduce exposure if price closes below the 50-day average or if Lifyorli launch data contradicts the thesis.
If CORT pulls back toward the $91 to $96 consolidation area without a new regulatory or clinical problem, compare price action with Lifyorli patient starts, Korlym volume, revenue guidance, and cash and investment balances.
Do not average down solely because the share price fell after a fast move. A failed FDA path, slow launch, or weak pipeline data can make historical support levels irrelevant.
Track Lifyorli prescriptions and patient starts, revenue progression against the $1.1 to $1.2 billion guidance, the December 17, 2026 Cushing’s PDUFA, MONARCH MASH and BELLA readouts, short interest, and any ALS Phase 3 update.
Lower confidence if growth depends on higher spending without revenue conversion, if cash declines faster than expected, if share count rises, or if a trial or regulatory result changes the addressable market.
Investment research summary
Corcept is a cortisol-modulation company. Customers and patients pay for Korlym in a specialized Cushing’s syndrome use case, while Lifyorli adds an approved oncology product used with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer. The economic model is high gross margin with substantial research, sales, and regulatory spending.
The moat comes from selective glucocorticoid receptor science, accumulated clinical data, patents, NCCN guideline inclusion, physician education, and experience navigating rare endocrine and oncology markets. It is not a network effect. Teva-style generic competition for Korlym, government rebate programs, and the need to prove each new indication can narrow it.
The thesis fails if Lifyorli does not convert its fast launch into durable sales, Cushing’s relacorilant cannot clear the FDA after the CRL and resubmission, Korlym pricing falls faster than volume grows, clinical trials disappoint, or legal and reimbursement issues consume the cash balance. A post-spike multiple magnifies each disappointment.
Management delivered a Q2 beat, raised 2026 guidance to $1.1 to $1.2 billion, added Lifyorli to NCCN guidelines, and preserved a net-cash balance sheet of about $535 million. The key test is whether the Korlym cash base converts into durable Lifyorli revenue and pipeline value without weakening per-share returns.
CORT sits at the intersection of rare endocrine disease, oncology, and cortisol biology. The long-term opportunity is a broader use of glucocorticoid receptor antagonism across cancer, metabolic disease, and ALS, but the company must earn each market through clinical evidence, regulatory approval, reimbursement, and physician adoption.
At roughly $12.38 billion of market value, 252x trailing EPS, and 14.9x trailing sales with a forward P/E near 29x, CORT is priced for an earnings inflection that the Lifyorli launch has begun to support. Net cash and raised guidance help, but they do not create a large margin of safety if the launch slows or the pipeline fails to replace the market’s growth assumptions.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CORT price | $114.49 close on July 31, 2026 | StockAnalysis market snapshot and history | August 3, 2026 |
| Market capitalization | $12.38 billion, verified as $114.49 x 108.098 million shares | StockAnalysis and SEC 10-Q, checked with financial_rigor.py | August 3, 2026 |
| Shares outstanding | 108,098,397 on July 22, 2026 | Corcept Q2 2026 Form 10-Q and StockAnalysis | August 3, 2026 |
| Q2 2026 revenue | $256.147 million, up 32 percent from $194.430 million; Korlym and authorized generic $208.583 million and Lifyorli $47.564 million | Corcept Q2 2026 Form 10-Q and Q2 2026 earnings press release | August 3, 2026 |
| Q2 2026 net income and EPS | $42.987 million net income and $0.36 diluted EPS, versus $35.149 million and $0.29 in Q2 2025 | Corcept Q2 2026 Form 10-Q and earnings press release | August 3, 2026 |
| FY2025 revenue | $761.407 million, up from $675.040 million in 2024, with net income of $99.652 million | Corcept FY2025 Form 10-K, cross-checked with StockAnalysis and Macrotrends | August 3, 2026 |
| 2026 revenue guidance | Raised to $1.1 to $1.2 billion in the Q2 2026 earnings release | Corcept Q2 2026 earnings press release | August 3, 2026 |
| Cash and investments | $544.6 million at June 30, 2026, compared with $515.4 million at March 31, 2026 | Corcept Q2 2026 Form 10-Q and earnings press release | August 3, 2026 |
| TTM free cash flow | $106.92 million, or about $0.99 per share | StockAnalysis cash flow and statistics pages | August 3, 2026 |
| Current valuation snapshot | About 252x TTM EPS, 14.9x TTM sales, 115.8x FCF, and a forward P/E near 29x from verified inputs | financial_rigor.py valuation verification and StockAnalysis ratios | August 3, 2026 |
| Lifyorli approval | FDA approved relacorilant plus nab-paclitaxel on March 25, 2026 for eligible platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | U.S. Food and Drug Administration | August 3, 2026 |
| Cushing’s NDA status | Relacorilant NDA resubmitted on June 17, 2026 with a Prescription Drug User Fee Act target date of December 17, 2026 | Corcept Q2 2026 Form 10-Q and press release | August 3, 2026 |
| Analyst view | Consensus Buy with a $135.25 average target; Canaccord, Piper Sandler, and H.C. Wainwright targets of $161 to $165 and Wolfe Research at $50 | StockAnalysis forecast and analyst news | August 3, 2026 |
| Technical snapshot | 50-day average $83.74, 200-day average $61.81, RSI 71.30, beta 0.46, 52-week range $28.66 to $122.21 | StockAnalysis statistics page | August 3, 2026 |
This CORT AI stock analysis is an informational tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario estimates based on available data and stated assumptions. Clinical, regulatory, financial, technical, and market conditions can change, and the analysis may be wrong. Verify current data and consult a qualified professional before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
